CStonePharmaceuticals 基石藥業 ( 於開曼群島註冊成立的有限公司 ) 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 (股份代號：2616) 自願 公告 ESMO 2025：基石藥業揭曉CS2009（PD-1/VEGF/CTLA-4三特異性抗體）Ⅰ期臨床試驗數據 本公告乃由基石藥業(「本公司」連同其附屬公司統稱(「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 ……………………………………………… ...

Core Viewpoint - 基石药业-B's stock price increased by 3.09% to 7.01 HKD, with a trading volume of 37.03 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO annual meeting in 2025 [1] Group 1: Clinical Pipeline Updates - 基石药业's core clinical pipeline includes CS2009, a PD-1/VEGF/CTLA-4 tri-specific antibody, and CS5001, an ROR1 antibody-drug conjugate (ADC) [1] - The I期 dose-escalation clinical data summary for CS2009 has been published on the ESMO website, covering data from 9 patients as of May 8, 2025 [1] - At the ESMO conference, 基石药业 will present preliminary data from the I期 dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data publication globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]

Core Viewpoint - The stock of Cornerstone Pharmaceuticals-B (02616) has seen an increase of over 3%, currently trading at 6.99 HKD with a transaction volume of 15.38 million HKD, following the announcement of key clinical data to be presented at the upcoming ESMO conference in 2025 [1] Group 1: Clinical Pipeline Updates - Cornerstone Pharmaceuticals is set to present preliminary data from its core clinical pipeline, specifically the CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody) and CS5001 (a ROR1 antibody-drug conjugate) at the 2025 ESMO annual meeting [1] - The abstract for CS2009 includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - At the ESMO conference, Cornerstone will showcase preliminary data from the I phase dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data presentation globally for a PD-1/VEGF/CTLA-4 tri-specific antibody [1]

Core Viewpoint - 基石药业-B (02616) is preparing to present clinical data for its drug candidates CS2009 and CS5001 at the upcoming ESMO annual meeting in October 2025, highlighting its advancements in cancer treatment [1] Group 1: Clinical Trials and Data - CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4, has preliminary data from a Phase I dose-escalation study involving 9 patients, which will be presented at the ESMO conference [1] - The company will showcase initial data from approximately 70 patients with advanced solid tumors for CS2009, marking the first known clinical data release globally for this tri-specific antibody [1] - CS5001, an antibody-drug conjugate targeting ROR1, has its Phase Ib clinical study design summary published on the ESMO website [1]

Core Insights - The upcoming European Society for Medical Oncology (ESMO) annual meeting will take place from October 17 to 21, 2025, in Berlin, Germany [1] - The company has announced that preliminary data for its core clinical pipeline, CS2009 (a PD-1/VEGF/CTLA-4 tri-specific antibody), will be presented at the ESMO conference [1] - CS2009's abstract includes data from 9 patients as of the submission deadline on May 8, 2025, fulfilling ESMO's submission requirements [1] - The company will showcase initial data from a Phase I dose-escalation study of CS2009 involving approximately 70 patients with advanced solid tumors, marking the first known clinical data on a PD-1/VEGF/CTLA-4 tri-specific antibody globally [1]